Scarica l'app Stockscreener
57.71
0.54%
0.31
Pre-mercato:
56.80
-0.91
-1.58%
Precedente Chiudi:
$57.40
Aprire:
$57.89
Volume 24 ore:
1.22M
Relative Volume:
0.91
Capitalizzazione di mercato:
$5.58B
Reddito:
$7.50M
Utile/perdita netta:
$-345.91M
Rapporto P/E:
-13.24
EPS:
-4.3602
Flusso di cassa netto:
$-280.51M
1 W Prestazione:
+5.83%
1M Prestazione:
+1.51%
6M Prestazione:
+49.28%
1 anno Prestazione:
+53.73%
Intervallo 1D:
$56.90
$58.53
Intervallo di 1 settimana:
$53.80
$58.53
Portata 52W:
$28.19
$63.95
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Nome
Xenon Pharmaceuticals Inc
Settore
Industria
Telefono
(604) 484-3300
Indirizzo
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
57.71 | 5.58B | 7.50M | -345.91M | -280.51M | -4.3602 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2025-09-03 | Ripresa | Wells Fargo | Overweight |
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-04 | Iniziato | Citigroup | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Iniziato | Goldman | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-10-19 | Iniziato | Raymond James | Outperform |
| 2022-08-29 | Iniziato | BofA Securities | Buy |
| 2022-07-21 | Iniziato | JP Morgan | Overweight |
| 2021-10-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-10-02 | Iniziato | SVB Leerink | Outperform |
| 2020-07-21 | Iniziato | Needham | Buy |
| 2020-06-01 | Ripresa | Jefferies | Buy |
| 2020-03-25 | Iniziato | Wedbush | Outperform |
| 2020-01-08 | Iniziato | William Blair | Outperform |
| 2019-09-20 | Iniziato | Guggenheim | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2017-03-13 | Iniziato | Jefferies | Buy |
| 2016-10-21 | Iniziato | Stifel | Buy |
| 2016-09-26 | Iniziato | Guggenheim | Buy |
| 2016-04-14 | Reiterato | Jefferies | Buy |
| 2015-10-30 | Ripresa | Jefferies | Buy |
| 2014-12-02 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie
XENON PHARMACEUTICALS INC (NASDAQ:XENE) Breakout Setup Combines 9/10 Technical Strength with 9/10 Consolidation Quality - ChartMill
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Seven new Xenon hires get stock awards priced at $56.04 - Stock Titan
Jennison Associates LLC Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Pictet Asset Management Holding SA Cuts Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon to Report Q1 2026 Financial Results on May 7, 2026 - The Manila Times
May 7 after the bell: Xenon to give Q1 update, host webcast - Stock Titan
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - MarketBeat
Xenon spikes, Theravance sinks after phase III readouts in March - BioWorld News
Xenon Pharmaceuticals Highlights Strong Phase III Azetukalner Data, Q3 NDA Plans at Bloom Burton Conference - MarketBeat
XENE Price Today: Xenon Pharmaceuticals Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Xenon Pharmaceuticals Reports Positive Phase 3 Azetukalner Results - HarianBasis.co
Peregrine Capital Management LLC Invests $7.84 Million in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Inc (XENE) Looking At a $2 Billion Opportunity Here - Yahoo Finance
Xenon's Phase 3 Supports A 'Buy' Despite Its Premium (NASDAQ:XENE) - Seeking Alpha
[ARS] Xenon Pharmaceuticals Inc. SEC Filing - Stock Titan
Xenon Pharmaceuticals (XENE) 2026 proxy details board elections and new equity plan - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Xenon (XENE), Biogen (BIIB) - The Globe and Mail
Needham Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $80 - Moomoo
RBC Raises Xenon Price Target, Cites Phase III Optimism for Epilepsy Drug - MSN
Stifel sees Xenon Pharmaceuticals stock reaching $2B in peak sales - Investing.com
Xenon Pharmaceuticals (XENE) Reports Positive Phase 3 Study Resu - GuruFocus
Xenon Pharma’s azetukalner shows 53% seizure reduction in trial By Investing.com - Investing.com South Africa
Xenon presents positive epilepsy drug trial data at AAN meeting - Investing.com
Xenon presents positive epilepsy drug trial data at AAN meeting By Investing.com - Investing.com Canada
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting - The Manila Times
Xenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results for Azetukalner in Focal Onset Seizures at AAN 2026 - Quiver Quantitative
Xenon Pharma’s azetukalner shows 53% seizure reduction in trial - Investing.com UK
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results - GlobeNewswire
Xenon to Present at Upcoming Investor Conferences - Sahm
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE) - MarketBeat
Xenon to Spotlight Neurology Pipeline at Series of 2026 Investor Conferences - TipRanks
Xenon Expands 2025 Inducement Equity Incentive Plan - The Globe and Mail
Xenon Pharmaceuticals Amends 2025 Inducement Equity Incentive Plan for Nasdaq Compliance and Employee Attraction 10 - Minichart
Xenon Pharmaceuticals (XENE) boosts 2025 inducement equity plan share reserve - Stock Titan
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Certain Restricted Stock Units of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 10-APR-2026. - marketscreener.com
Certain Stock Options of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 10-APR-2026. - marketscreener.com
Certain Common Shares of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 10-APR-2026. - marketscreener.com
Published on: 2026-04-09 12:46:57 - baoquankhu1.vn
Xenon Pharmaceuticals to present azetukalner epilepsy data at AAN By Investing.com - Investing.com Australia
Xenon Pharmaceuticals to present azetukalner epilepsy data at AAN - Investing.com
Xenon Pharmaceuticals Inc Azioni (XENE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):